Ascelia Pharma AB (publ) Cash Flow Conversion Efficiency

Latest as of September 2025: -0.137x

Ascelia Pharma AB (publ) cash flow conversion efficiency. Based on the latest financial reports, Ascelia Pharma AB (publ) (ACE) has a cash flow conversion efficiency ratio of -0.137x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-15.66 Million ≈ $-1.69 Million USD) by net assets (Skr114.40 Million ≈ $12.31 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Ascelia Pharma AB (publ) (2017–2024)

Cash flow conversion efficiency of Ascelia Pharma AB (publ) from 2017 to 2024. This chart illustrates how Ascelia Pharma AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View Ascelia Pharma AB (publ) share price for real-time trading data and today's change.

Ascelia Pharma AB (publ) Cash Flow Conversion Ratio Explained

Ascelia Pharma AB (publ) cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Ascelia Pharma AB (publ) Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Ascelia Pharma AB (publ) ranked by their cash flow conversion efficiency. Also see Ascelia Pharma AB (publ) market cap and net worth for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Ensysce Biosciences Inc NASDAQ:ENSC	1.767x
Hudson Investment Group Ltd AU:HGL	-0.011x
Jinzhou Port Co Ltd B SHG:900952	-9.376x
KIBO ENERGY PLC EO -001 F:1I8	N/A
Tigi Ltd TA:TIGI	-1.090x
GLG Corp Ltd AU:GLE	0.125x
ProMIS Neurosciences Inc. NASDAQ:PMN	-1.108x
TME Pharma N.V. PA:ALTME	0.353x

Annual Cash Flow Conversion Efficiency for Ascelia Pharma AB (publ) (2017–2024)

The table below shows the annual cash flow conversion efficiency of Ascelia Pharma AB (publ) from 2017 to 2024. Review Ascelia Pharma AB (publ) free cash flow to debt ratio to assess the company's free cash flow relative to its total liabilities.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	Skr78.94 Million ≈ $8.50 Million	Skr-62.84 Million ≈ $-6.76 Million	-0.796x	+53.33%
2023-12-31	Skr74.33 Million ≈ $8.00 Million	Skr-126.79 Million ≈ $-13.64 Million	-1.706x	-146.30%
2022-12-31	Skr180.86 Million ≈ $19.46 Million	Skr-125.26 Million ≈ $-13.48 Million	-0.693x	-82.92%
2021-12-31	Skr307.83 Million ≈ $33.13 Million	Skr-116.56 Million ≈ $-12.54 Million	-0.379x	-4.51%
2020-12-31	Skr236.06 Million ≈ $25.40 Million	Skr-85.53 Million ≈ $-9.20 Million	-0.362x	-132.65%
2019-12-31	Skr237.06 Million ≈ $25.51 Million	Skr-36.92 Million ≈ $-3.97 Million	-0.156x	-41.74%
2018-12-31	Skr276.07 Million ≈ $29.71 Million	Skr-30.33 Million ≈ $-3.26 Million	-0.110x	+41.43%
2017-12-31	Skr111.73 Million ≈ $12.02 Million	Skr-20.96 Million ≈ $-2.26 Million	-0.188x	--

About Ascelia Pharma AB (publ)

ST:ACE Sweden Biotechnology

Market Cap

$7.35 Million

Skr68.26 Million SEK

Market Cap Rank

#27676 Global

#601 in Sweden

Share Price

Skr0.54

Change (1 day)

-3.24%

52-Week Range

Skr0.48 - Skr3.43

All Time High

Skr900.24